Sign in

Private company

Biohaven Pharmaceutical Holding Co Ltd.

Pharmaceutical preparations company based in New Haven, British Virgin Islands2

In its 2022 annual report the company says: “We are a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders.”51

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersNew Haven, United States2
  • Incorporated inVirgin Islands, British3
  • Business address215 Church Street, New Haven, Ct 065103
  • Filer categoryLarge accelerated filer3
  • Legal formcompany limited by shares2
  • LEI5299007STZTNN32O99202
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o Maples Corporate Services (BVI) Limited, Kingston Chambers, PO Box 173, VG1110 Road Town, British Virgin Islands2
  • Registered withRegistry of Corporate Affairs (British Virgin Islands Financial Services Commission), 17921782

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

80.2%Gross margin4
-152.2%Operating margin4
-183.0%Net margin4
626.9%Revenue growth, 20214
-$832.8MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue8¢$91.7M
  • Research and development31¢$361.3M
  • Selling, general and admin61¢$713.5M
  • Income tax0¢$5.1M

Out of $462.5M in revenue.4 The company lost money this year.

Financial statements

Revenue54$462.5M in 2021
0$200.0M$400.0M$600.0M2018: $0$020182019: $0$020192020: $63.6M$63.6M20202021: $462.5M$462.5M2021+627%
Gross profit54$370.8M in 2021
0$100.0M$200.0M$300.0M$400.0M2018: $0$020182019: $0$020192020: $45.9M$45.9M20202021: $370.8M$370.8M2021+707%
Operating income67854-$704.0M in 2021+7161% since 2015
-$800.0M-$600.0M-$400.0M-$200.0M02015: -$9.7M-$9.7M20152016: -$60.6M-$60.6M2016+525%2017: -$107.6M-$107.6M2017+77%2018: -$224.6M-$224.6M2018+109%2019: -$479.1M-$479.1M2019+113%2020: -$645.4M-$645.4M2020+35%2021: -$704.0M-$704.0M2021+9%
Net income67854-$846.6M in 2021+8310% since 2015
-$1.0B-$750.0M-$500.0M-$250.0M02015: -$10.1M-$10.1M20152016: -$63.5M-$63.5M2016+531%2017: -$127.2M-$127.2M2017+100%2018: -$240.9M-$240.9M2018+89%2019: -$528.8M-$528.8M2019+119%2020: -$766.8M-$766.8M2020+45%2021: -$846.6M-$846.6M2021+10%
Fiscal year2015201620172018201920202021
Revenue$05$04$63.6M4$462.5M4
Cost of revenue$05$04$17.7M4$91.7M4
Gross profit$05$04$45.9M4$370.8M4
Research and development$7.6M6$55.5M7$89.4M8$190.0M5$344.7M4$229.0M4$361.3M4
Selling, general and admin$34.6M5$134.4M4$462.3M4$713.5M4
Operating expenses$1.1B4
Operating income-$9.7M6-$60.6M7-$107.6M8-$224.6M5-$479.1M4-$645.4M4-$704.0M4
Interest$385.0K7$906.0K7$38.0K7
Income before tax-$843.3M4
Income tax$90.0K7$1.0M8$467.0K5$419.0K4$10.2M4$5.1M4
Net income-$10.1M6-$63.5M7-$127.2M8-$240.9M5-$528.8M4-$766.8M4-$846.6M4
Earnings per share-$10.914-$13.064-$13.094
Earnings per share (diluted)-$10.914-$13.064-$13.094
Shares (weighted, basic)64.7M shares4
Shares (weighted, diluted)64.7M shares4

Compare Biohaven Pharmaceutical Holding Co Ltd. with another company

Corporate structure

Biohaven Pharmaceutical Holding Co Ltd. is part of a group headed by Pfizer. 367 entities, 63 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Biohaven Pharmaceutical Holding Co Ltd.

  • Capital International Investors Filed SC 13G/A on Biohaven Pharmaceutical Holding Co Ltd., latest Jun 10, 2022 (2 filings since Feb 11, 2022)
  • Capital World Investors Filed SC 13G/A on Biohaven Pharmaceutical Holding Co Ltd., latest Jun 10, 2022 (3 filings since Feb 11, 2022)
  • BlackRock Filed SC 13G/A on Biohaven Pharmaceutical Holding Co Ltd., latest Feb 3, 2022
  • Pfizer New York, New York, United States
    • Biohaven Pharmaceutical Holding Co Ltd. New Haven, Connecticut, United States
    • C.P. Pharmaceuticals International C.V. New York, New York, United States
      • Ferrosan Copenhagen, Denmark
      • PF PRISM Holdings S.a r.l. (PF PRISM Holdings S.à r.l.) Subsidiary · Luxembourg, Luxembourg
      • PFIZER COMMERCIAL HOLDINGS TRAE KFT. Subsidiary · Budapest, Hungary
      • Pfizer Investment Holdings S. a r.l. (Pfizer Investment Holdings S. à r.l.) Subsidiary · Luxembourg, Luxembourg
      • PFIZER MANUFACTURING SERVICES UNLIMITED COMPANY Subsidiary · Cork, Ireland
      • PFIZER SERVICE COMPANY IRELAND UNLIMITED COMPANY Subsidiary · Dublin, Ireland
      • PFIZER SHARED SERVICES UNLIMITED COMPANY Subsidiary · Dublin, Ireland
      • PFIZER WORLDWIDE SERVICES UNLIMITED COMPANY Subsidiary · Dublin, Ireland
      • PRISM HOLDINGS B.V. Subsidiary · Capelle Aan Den Ijssel, Netherlands
    • Hospira Wilmington, Delaware, United States
      • HOSPIRA UK LIMITED Subsidiary · Royal Leamington Spa, United Kingdom
    • Pfizer AG Zurich, Switzerland
    • Pfizer Aktiebolag Stockholm, Sweden
    • Pfizer Corporation Austria Gesellschaft mbH Vienna, Austria
    • PFIZER GROUP LUXEMBOURG S.À R.L. Luxembourg, Luxembourg
      • Pfizer Deutschland GmbH Berlin, Germany
        • PFIZER MANUFACTURING DEUTSCHLAND GMBH Subsidiary · Illertissen, Germany
        • PFIZER PHARMA GMBH Subsidiary · Berlin, Germany
      • PFIZER INVESTMENT CAPITAL UNLIMITED COMPANY Subsidiary · Dublin, Ireland
      • PFIZER PHARMA PFE GMBH Subsidiary · Berlin, Germany
      • PFIZER SPAIN HOLDINGS B.V. Subsidiary · Capelle Aan Den Ijssel, Netherlands
      • PFIZER, SPOL. S R.O. Subsidiary · Vysocina, Czechia
    • PFIZER HOLDING FRANCE Paris, France
    • Pfizer Ireland Pharmaceuticals Cork, Ireland
    • PFIZER IRELAND VENTURES UNLIMITED COMPANY Cork, Ireland
    • Pfizer SA Brussels, Belgium
    • Pharmacia International B.V. Capelle aan den IJssel, Netherlands
      • Pfizer B.V. Capelle aan den IJssel, Netherlands
        • PFIZER PFE B.V. Subsidiary · Capelle Aan Den Ijssel, Netherlands
      • PFIZER MANUFACTURING BELGIUM Subsidiary · Puurs-Sint-Amands, Belgium
        • PFIZER FINANCIAL SERVICES Subsidiary · Puurs-Sint-Amands, Belgium
    • G. D. Searle & Company Subsidiary · New York City
    • Gödecke Subsidiary · Leipzig, Germany
    • Parke-Davis Subsidiary · Detroit
    • Pfizer (Canada) Subsidiary · Kirkland, Quebec, Canada
    • Pfizer UK Subsidiary · Tadworth
    • 356 Royalty Inc. Subsidiary · Delaware, United States
    • Agouron Pharmaceuticals, LLC Subsidiary · California, United States
    • AH Robins LLC Subsidiary · Delaware, United States
    • AHP HOLDINGS BV Subsidiary · Capelle Aan Den Ijssel, Netherlands
    • AHP Manufacturing B.V. Subsidiary · Capelle aan den IJssel, Netherlands
      • AHP MANUFACTURING B. V. Branch · Capelle aan den IJssel, Netherlands
    • Alpharma Pharmaceuticals LLC Subsidiary · Delaware, United States
    • Alpharma Specialty Pharma LLC Subsidiary · Delaware, United States
    • American Food Industries LLC Subsidiary · Delaware, United States
    • and 286 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Biohaven Pharmaceutical Holding Co Ltd. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$19.3M4 Dec 31, 2021$11.5M4 Dec 31, 2020+68.5%
Accumulated depreciation$4.6M4 Dec 31, 2021$2.1M4 Dec 31, 2020+118.2%
Property and equipment, net$14.7M4 Dec 31, 2021$9.3M4 Dec 31, 2020+57.3%
Finance-lease assets$8.7M4 Dec 31, 2021$13.9M4 Dec 31, 2020−37.2%
Operating-lease assets (leased space)$5.2M4 Dec 31, 2021$6.0M4 Dec 31, 2020−12.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$171.9M4 Dec 31, 2021$132.1M4 Dec 31, 2020+30.1%
Marketable securities, current$192.6M4 Dec 31, 2021$223.2M4 Dec 31, 2020−13.7%
Debt securities available for sale$192.6M4 Dec 31, 2021$223.2M4 Dec 31, 2020−13.7%
Stakes in other companies (equity method)$04 Dec 31, 2021$1.2M4 Dec 31, 2020−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$56.4M4 Dec 31, 2021$39.1M4 Dec 31, 2020+44.4%
Finite-lived intangibles, gross$41.5M4 Dec 31, 2021$41.5M4 Dec 31, 20200%
Accumulated amortization$4.9M4 Dec 31, 2021$2.4M4 Dec 31, 2020+103.9%
Finite-lived intangibles, net$36.6M4 Dec 31, 2021$39.1M5 Dec 31, 2020−6.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$80.6M4 Dec 31, 2021$39.6M4 Dec 31, 2020+103.7%
Raw materials$04 Dec 31, 2021$931.0K4 Dec 31, 2020−100.0%
Work in process$159.1M4 Dec 31, 2021$33.3M4 Dec 31, 2020+378.2%
Finished goods$9.3M4 Dec 31, 2021$5.4M4 Dec 31, 2020+72.7%

Leadership

Who has led Biohaven Pharmaceutical Holding Co Ltd., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Vlad Coric2017–2022

Chief financial officer

  1. James Engelhart2017–2021
  2. Matthew Buten2022
20202025
Board members and other officers (19)

Timeline

  1. Oct 3, 20228-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer32
  2. Sep 29, 20228-K Shareholder vote; Other events33
  3. Sep 27, 20228-K Regulation FD disclosure34
  4. Sep 23, 20228-K Other events35
  5. Sep 23, 20228-K Regulation FD disclosure36
  6. Sep 19, 20228-K Other events37
  7. Sep 19, 20228-K Other events38
  8. Aug 5, 20228-K Results of operations39
  9. Jun 28, 20228-K Other events40
  10. May 11, 20228-K Entered a material agreement41
  11. May 10, 20228-K Other events42
  12. May 10, 20228-K Results of operations43
  13. May 3, 2017New chief executive Vlad Coric becomes CEO11

Calendar

When it reported results

  1. Aug 5, 2022Reported quarterly or annual results39
  2. May 10, 2022Reported quarterly or annual results43
  3. Feb 25, 2022Reported quarterly or annual results44
  4. Jan 10, 2022Reported quarterly or annual results45
  5. Nov 9, 2021Reported quarterly or annual results46
  6. Oct 6, 2021Reported quarterly or annual results47

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

124 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 26 major events, 65 insider forms, 6 large holders, 23 other. The latest 20:

  1. Oct 14, 202215-12G EDGAR
  2. Oct 3, 20228-K EDGAR
  3. Oct 3, 2022POSASR EDGAR
  4. Oct 3, 2022S-8 POS EDGAR
  5. Oct 3, 2022S-8 POS EDGAR
  6. Oct 3, 2022S-8 POS EDGAR
  7. Oct 3, 2022S-8 POS EDGAR
  8. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  9. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  10. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  11. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  12. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  13. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  14. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  15. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  16. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  17. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  18. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  19. Oct 3, 20224 PRIMARY DOCUMENT EDGAR
  20. Oct 3, 20224 PRIMARY DOCUMENT EDGAR

The 124 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 2 buys and 9 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 19, 2022Bailey GregoryDirectorBuy38,000$148.04$5.6MForm 4
May 10, 2022Clark George C.VP, Chief Accounting OfficerSale4,200$141.50$594.3KForm 4
Jan 19, 2022Clark George C.VP, Chief Accounting OfficerSale9,375$117.01$1.1MForm 4
Dec 20, 2021Clark George C.VP, Chief Accounting OfficerSale1,915$123.84$237.2KForm 4
Dec 20, 2021GREGORY JULIA PDirectorSale12,000$125.00$1.5MForm 4
Dec 15, 2021Stock ElyseChief Medical OfficerSale21,919$105.48$2.3MForm 4
Dec 14, 2021Stock ElyseChief Medical OfficerSale6,939$105.02$728.7KForm 4
Dec 10, 2021Engelhart JamesStrategic AdvisorSale35,000$102.55$3.6MForm 4
Nov 29, 2021Doogan DeclanDirectorSale24,525$112.80$2.8MForm 4
Nov 16, 2021Doogan DeclanDirectorSale37,740$116.65$4.4MForm 4
Nov 10, 2021CHILDS JOHN WDirectorBuy5,000$122.87$614.4KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Biohaven Pharmaceutical Holding Co Ltd. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBiohaven Pharmaceutical Holding Co Ltd.1
  • CIK0001689813
  • Filer statusLarge accelerated filer1
  • Incorporated inVirgin Islands, British1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address215 Church Street, New Haven, CT 065101
  • Phone203-404-04101
  • Shares outstanding71,494,798 as of Aug 4, 202210
  • Public float$4.3B as of Jun 30, 20214
  • On EDGAR sinceNov 10, 20161
  • Filings530 in all: 4 (243), 8-K (97), 3 (23), 10-Q (17), 5 (15), DEFA14A (15), SC 13G/A (13), 424B3 (10)1
    All 40 form types

    4/A (9), 424B5 (8), SC 13G (8), CORRESP (7), 10-K (5), DEF 14A (5), EFFECT (4), S-1 (4), S-8 (4), S-8 POS (4), 424B7 (3), 8-K/A (3), CT ORDER (3), DRS (3), SC 13D (3), UPLOAD (3), 3/A (2), 424B4 (2), S-1/A (2), S-1MEF (2), S-3ASR (2), 15-12G (1), 25-NSE (1), 8-A12B (1), CERTNYS (1), D (1), DEFM14A (1), DRS/A (1), DRSLTR (1), POSASR (1), PREM14A (1), PRER14A (1)

  • Latest filingsAnnual report (10-K) Feb 25, 2022
    Quarterly report (10-Q) Aug 5, 2022
    Proxy statement (DEF 14A) Mar 11, 2022
    Latest 8-K (8-K) Oct 3, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
  37. 37
    SEC EDGAROther events
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
    SEC EDGAROther events
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51